Search - tctmd.com

Displaying 281 - 300 of 378

Sort: Relevancy | Date

Presentation TCT 2015

Featured Lecture: New DAPT Duration Recommendations

Presenter: John A. Bittl, E. Magnus Ohman

October 11, 2015

Presentation TCT 2015

Lessons From the TAXUS Liberté/Prasugrel Substudy

Presenter: John A. Bittl, E. Magnus Ohman, David P. Lee

October 11, 2015

Presentation TCT 2015

Bare-Metal and Drug-Eluting Stents: Devices, Indications, and Outcomes

Presenter: Emmanouil S. Brilakis, Rajesh V Swaminathan

October 11, 2015

Presentation TCT 2015

Debate: What Is the Ideal Duration of DAPT After DES? Shorter Is Best (for Most)!

Presenter: John A. Bittl, E. Magnus Ohman, Hyeon-Cheol Gwon

October 11, 2015

Presentation TCT 2015

Debate: What Is the Ideal Duration of DAPT After DES? Longer Is Better (for Most)!

Presenter: John A. Bittl, E. Magnus Ohman, David P. Lee

October 11, 2015

Presentation TCT 2015

What Have We Learned From All-Comers Head-to-Head DES Trials II? The COMPARE Trials

Presenter: Stephen G. Ellis, John A. Ormiston, Pieter C. Smits

October 11, 2015

Presentation TCT 2015

What Have We Learned From All-Comers Head-to-Head DES Trials I? The SORT OUT Trial

Presenter: Stephen G. Ellis, John A. Ormiston, Evald H. Christiansen

October 11, 2015

Presentation TCT 2015

Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY Update

Presenter: Stephen G. Ellis, John A. Ormiston, Dean J. Kereiakes

October 11, 2015

Presentation TCT 2015

Update on Biolimus-Eluting Stent Platforms: BioMatrix and Nobori Program Update

Presenter: Stephen G. Ellis, John A. Ormiston, Philip M. Urban

October 11, 2015

Presentation TCT 2015

Durable-Polymer DES 5-Year Outcomes: RESOLUTE Update

Presenter: Stephen G. Ellis, John A. Ormiston, Sigmund Silber

October 11, 2015

Presentation TCT 2015

Durable-Polymer DES 5-Year Outcomes: XIENCE/PROMUS and PROMUS Element Update

Presenter: Stephen G. Ellis, John A. Ormiston, Gregg W. Stone

October 11, 2015

Presentation TCT 2015

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? No, This Theoretical Goal Does Not Hold Up Under Scrutiny!

Presenter: Stephen G. Ellis, John A. Ormiston, Tullio Palmerini

October 11, 2015

Presentation TCT 2015

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? Yes, Eliminating the Polymer to Leave Behind a Bare-Metal Stent Surface Is a Desirable and Clinically Meaningful Goal!

Presenter: Stephen G. Ellis, John A. Ormiston, Robert A. Byrne

October 11, 2015

Presentation TCT 2015

Clinical Outcomes of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Presenter: Stephen G. Ellis, John A. Ormiston, Sripal Bangalore

October 11, 2015

Presentation TCT 2015

Design of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Presenter: Stephen G. Ellis, John A. Ormiston

October 11, 2015

Presentation CICT 2015

Drug Eluting Femoral Stents Where does it fit in my practice?

Presenter: Yazan Khatib

July 31, 2015

Presentation CCVVC 2015

Endovascular Management of SFA Instent Restenosis: Role of Atherectomy Drug-Eluting Stents

Presenter: Craig M. Walker

June 18, 2015

Presentation CCVVC 2015

Drug Eluting Stents in the treatment of SFA disease: Data and Current Trends

Presenter: Suhail Dohad

June 18, 2015

Presentation Fellows 2015

Drug-Eluting Stents: Past, Present, and Future

Presenter: Manish A. Parikh, Roxana Mehran, Gregg W. Stone

May 15, 2015

Presentation AHA 2014

Long-term Outcome of Biodegradable Compared to Durable Polymer Drug-Eluting Stents and Bare Metal Stents – Main Results of a Prospective Randomized Trial

Presenter: C.Kaiser

November 16, 2014

Advertisement

Featured Lecture: New DAPT Duration Recommendations

Lessons From the TAXUS Liberté/Prasugrel Substudy

Bare-Metal and Drug-Eluting Stents: Devices, Indications, and Outcomes

Debate: What Is the Ideal Duration of DAPT After DES? Shorter Is Best (for Most)!

Debate: What Is the Ideal Duration of DAPT After DES? Longer Is Better (for Most)!

What Have We Learned From All-Comers Head-to-Head DES Trials II? The COMPARE Trials

What Have We Learned From All-Comers Head-to-Head DES Trials I? The SORT OUT Trial

Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY Update

Update on Biolimus-Eluting Stent Platforms: BioMatrix and Nobori Program Update

Durable-Polymer DES 5-Year Outcomes: RESOLUTE Update

Durable-Polymer DES 5-Year Outcomes: XIENCE/PROMUS and PROMUS Element Update

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? No, This Theoretical Goal Does Not Hold Up Under Scrutiny!

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? Yes, Eliminating the Polymer to Leave Behind a Bare-Metal Stent Surface Is a Desirable and Clinically Meaningful Goal!

Clinical Outcomes of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Design of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Drug Eluting Femoral Stents Where does it fit in my practice?

Endovascular Management of SFA Instent Restenosis: Role of Atherectomy Drug-Eluting Stents

Drug Eluting Stents in the treatment of SFA disease: Data and Current Trends

Drug-Eluting Stents: Past, Present, and Future

Long-term Outcome of Biodegradable Compared to Durable Polymer Drug-Eluting Stents and Bare Metal Stents – Main Results of a Prospective Randomized Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content